You are here

New Heparin Production Plants

17 Dec 2009

Since Bioiberica was founded in 1975, Heparin has been one of the company’s most important products.

Investments in new production facilities have consolidated Bioiberica as the world leader in Heparin production.


This year, the production facilities in Poland have been expanded and new plants have been opened in the United States and Brazil.


With these investments, Bioiberica has increased its production capacity and flexibility and continues to provide clients with the best service.


Moreover, the fact that the production network is set up in several countries helps the company improve its production management and ensure control of raw materials to guarantee complete product traceability and maximum quality.


Further investments are expected in 2010 in two other production units in Europe.

Related News

23 May 2024

A crucial initiative to prevent shortages of critical medicines in the European Union.

28 Sep 2021

The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by

4 Aug 2021
  • Bioiberica produces 20% of the world's Heparin API.
  • Heparin saves around a hundred million lives every year.
  • One out of every 5 doses of heparin administered in the world comes from Bioiberica.